Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Synthesis and characterization of novel denosumab/magnesium-based metal organic frameworks nanocomposite prepared by ultrasonic route as drug delivery system for the treatment of osteoporosis

View through CrossRef
Introduction: The metal-organic frameworks (MOF) have shown fascinating possibilities in biomedical applications, and designing a drug delivery system (DDS) based on the MOF is important. This work aimed at developing a suitable DDS based on Denosumab-loaded Metal Organic Framework/Magnesium (DSB@MOF (Mg)) for attenuating osteoarthritis.Materials and Methods: The MOF (Mg) (Mg3(BPT)2(H2O)4) was synthesized using a sonochemical protocol. The efficiency of MOF (Mg) as a DDS was evaluated by loading and releasing DSB as a drug. In addition, the performance of MOF (Mg) was evaluated by releasing Mg ions for bone formation. The MOF (Mg) and DSB@MOF (Mg) cytotoxicity towards the MG63 cells were explored by MTT assay.Results: MOF (Mg) characterized by using XRD, SEM, EDX, TGA, and BET. Drug loading, and releasing experiments proved that DSB was loaded on the MOF (Mg) and approximately 72% DSB was released from it after 8 h. The characterization techniques showed that MOF (Mg) was successfully synthesized with good crystal structure and thermal stability. The result of BET showed that MOF (Mg) had high surface areas and pore volume. This is the reason why its 25.73% DSB was loaded in the subsequent drug-loading experiment. Drug release and ion release experiments indicated DSB@MOF (Mg) had a good controlled release of DSB and Mg ions in solution. Cytotoxicity assay confirmed that the optimum dose of it had excellent biocompatibility and could stimulate the proliferation of MG63 cells as time went on.Conclusion: Due to the high loading amount of DSB and releasing time, DSB@MOF (Mg) can be promising as a suitable candidate for relieving bone pain caused by osteoporosis, with ossification-reinforcing functions.
Title: Synthesis and characterization of novel denosumab/magnesium-based metal organic frameworks nanocomposite prepared by ultrasonic route as drug delivery system for the treatment of osteoporosis
Description:
Introduction: The metal-organic frameworks (MOF) have shown fascinating possibilities in biomedical applications, and designing a drug delivery system (DDS) based on the MOF is important.
This work aimed at developing a suitable DDS based on Denosumab-loaded Metal Organic Framework/Magnesium (DSB@MOF (Mg)) for attenuating osteoarthritis.
Materials and Methods: The MOF (Mg) (Mg3(BPT)2(H2O)4) was synthesized using a sonochemical protocol.
The efficiency of MOF (Mg) as a DDS was evaluated by loading and releasing DSB as a drug.
In addition, the performance of MOF (Mg) was evaluated by releasing Mg ions for bone formation.
The MOF (Mg) and DSB@MOF (Mg) cytotoxicity towards the MG63 cells were explored by MTT assay.
Results: MOF (Mg) characterized by using XRD, SEM, EDX, TGA, and BET.
Drug loading, and releasing experiments proved that DSB was loaded on the MOF (Mg) and approximately 72% DSB was released from it after 8 h.
The characterization techniques showed that MOF (Mg) was successfully synthesized with good crystal structure and thermal stability.
The result of BET showed that MOF (Mg) had high surface areas and pore volume.
This is the reason why its 25.
73% DSB was loaded in the subsequent drug-loading experiment.
Drug release and ion release experiments indicated DSB@MOF (Mg) had a good controlled release of DSB and Mg ions in solution.
Cytotoxicity assay confirmed that the optimum dose of it had excellent biocompatibility and could stimulate the proliferation of MG63 cells as time went on.
Conclusion: Due to the high loading amount of DSB and releasing time, DSB@MOF (Mg) can be promising as a suitable candidate for relieving bone pain caused by osteoporosis, with ossification-reinforcing functions.

Related Results

Denosumab-bbdz: A Review of the Interchangeable Biosimilar for the Treatment of Osteoporosis
Denosumab-bbdz: A Review of the Interchangeable Biosimilar for the Treatment of Osteoporosis
Objective: The objective of this article is to review the pharmacologic and clinical profile of denosumab-bbdz (GP2411, SDZ-deno), the first interchangeable RAN...
Underweight Sebagai Faktor Resiko Osteoporosis Pada Lansia
Underweight Sebagai Faktor Resiko Osteoporosis Pada Lansia
Osteoporosis is a bone disease characterized by decreased bone density. The incidence of osteoporosis increases with age, especially age ≥ 50 years. Research from the International...
MON-808 Multiple Vertebral Fractures After A Single Dose Of Denosumab
MON-808 Multiple Vertebral Fractures After A Single Dose Of Denosumab
Abstract Disclosure: J.L. Ryan: None. L.S. Eldeiry: None. Background: Denosumab, a human monoclonal antibody inhibitor of RANKL(Receptor Activat...
Resource-efficient technology for the utilization of serpentine technogenic waste with the production of magnesium oxide
Resource-efficient technology for the utilization of serpentine technogenic waste with the production of magnesium oxide
The article discusses the possibility of using serpentine and serpentine waste from Zhitikara deposit for the production of inorganic magnesium compounds: MgSO4, Mg(OH)2 and MgO. T...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Analgesic effect of neoadjuvant denosumab in Grade III giant cell tumor of bone.
Analgesic effect of neoadjuvant denosumab in Grade III giant cell tumor of bone.
Objective: To assess the pain relief after denosumab use in grade III giant cell tumor of bone (GCT-B). Study Design: Retrospective Cohort study. Setting: Department of Orthopedic ...

Back to Top